alkindi
diurnal europe b.v. - hidrokortizon - nadledvična insuficienca - kortikosteroidi za sistemsko uporabo - zamenjava terapije nadledvične žleze, cerebrovaskularnih pri dojenčkih, otrocih in mladostnikih (od rojstva do < 18 let).
cortef 10 mg tablete
sanolabor, d.d. - hidrokortizon - tableta - hidrokortizon 10 mg / 1 tableta - hidrokortizon
zessly
sandoz gmbh - infliksimab - arthritis, psoriatic; psoriasis; crohn disease; arthritis, rheumatoid; colitis, ulcerative; spondylitis, ankylosing - imunosupresivi - zdravljenje revmatoidni artritis, crohnova bolezen, ulcerozni kolitis, ankilozirajoči spondilitis, psoriatični artritis in luskavica.
hydrocortisone roussel 10 mg tablete
sanolabor, d.d. - tableta - hidrokortizon
hydrocortison 10 mg jenapharm tablete
sanolabor, d.d. - tableta - hidrokortizon
hydrocortison galen 10 mg tablete
altamedics d.o.o. - tableta - hidrokortizon
hydrocortison tablete 10 mg
tableta - hidrokortizon
fluad tetra
seqirus netherlands b.v. - a/darwin/9/2021 (h3n2) - like strain (a/darwin/6/2021, ivr-227) / a/victoria/4897/2022 (h1n1) pdm09-like strain (a/victoria/4897/2022, ivr-238) / b/phuket/3073/2013-like strain (b/phuket/3073/2013, bvr-1b) / influenza virus b/austria/1359417/2021-like strain (b/austria/1359417/2021, bvr-26) - gripa, človek - cepiva - profilaksa gripe pri starejših (65 let in starejši). fluad tetra je treba uporabljati v skladu z uradnimi priporočili.
zoonotic influenza vaccine seqirus
seqirus s.r.l. - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - cepiva - active immunisation against h5 subtype of influenza a virus.
trodelvy
gilead sciences ireland uc - sacituzumab govitecan - breast neoplasms; triple negative breast neoplasms - antineoplastična sredstva - trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mtnbc) who have received two or more prior systemic therapies, including at least one of them for advanced disease.